WHO warns: Never underestimate the threat of Omikejung

On Tuesday, December 14, WHO Director-General Tedros Adhanom Ghebreyesus said that 77 countries and territories have reported the emergence of Omicron so far, but the reality is that Omicron may have spread to most countries but has not been detected.

Don't underestimate the dangers [of Omiljung], even if the symptoms they cause are not severe, but the number of cases that spread can once again overwhelm unprepared health systems.

Meanwhile, WHO Senior Adviser Bruce Aylward said at the briefing:

We fear that people will easily conclude that this is a mild disease. A more transmissible virus (Omikron) can cause just as much or even more damage than a more severe but less contagious virus (Delta).

He added that the combination of increased social activity during the holidays and strains of the virus that are more likely to spread can lead to "extremely dangerous situations.")

Wall Street has previously mentioned that The South African doctor Angelique Coetzee, who was the first to "warn" of the new strain, said that the patients with Omikejong showed mild symptoms, almost no severe diseases, typical symptoms of fatigue, limb pain and cough. It was noted that this manifestation was in stark contrast to dyspnea, low blood oxygen levels, and loss of smell and taste as manifested by delta virus infection.

However, although severe illness is uncommon, its rate of transmission is staggering. Taking last week's cases in the UK, which have doubled in an average of 2.5 days in the past two weeks, the Uk Ministry of Health expects that Omi kerong may replace Delta as the country's leading epidemic strain in the coming weeks, and the number of people infected with the virus may exceed 1 million by the end of this month.

Pfizer CEO Albert Bourla has also previously said that Omilon looks milder but spreads faster.

Not only does it spread quickly, epidemiological data in South Africa show that the risk of reinfection caused by the Omikeron variant increases by a factor of 3 compared to previous variants.

Research data on Omilon is constantly being updated, and earlier wall Street articles show that data from Discovery Health, South Africa's largest health insurance provider, show that two doses of the Pfizer vaccine have a 70% protection rate for hospital admission after infection with the Omilkejung variant, 33% effective in preventing Omiljung infection, and 80% effective in preventing Delta infection.

Pfizer said today that its covid-19 oral drug Paxlovid is close to 90 percent effective in preventing hospitalizations and deaths in high-risk patients, and recent experimental data suggest that the oral drug is still effective against the fast-spreading drug king Omexron.

This article is from Wall Street Insights, welcome to download the APP to see more